Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Rituximab Retreatment Dosing in RA
NCT01126541Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2006
- Primary completion
- Nov 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Started Sep 2006; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01126541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01126541.